Cefmetazole


Full Generic Medicine Info
Dosage/Direction for Use

Parenteral
Mixed bacterial infections, Prophylaxis of anaerobic bacterial infections, Prophylaxis of mixed bacterial infections, Anaerobic bacterial infections, Gonorrhoea
Adult: 0.5-1 g every 12 hr via IM inj or slow IV inj over 3-5 minutes. Severe infections: 3-4 g daily, given in divided doses every 6-8 hr. Dose can also be given via IV infusion over 10-60 minutes.
Renal impairment: Interval between doses: 12, 16, or 24 hr in patients with mild, moderate or severe renal impairment, respectively. Patients with virtually no renal function: dose may be given every 48 hr after hemodialysis.
Contraindications
Hypersensitivity to cephalosporins.
Special Precautions
History of allergy; porphyria; renal impairment. Monitor renal and haematological states during prolonged and high-dose thearapy. Lactation.
Adverse Reactions
Hypersensitivity reactions; nephrotoxicity; neutropenia; thrombocytopenia; agranulocytosis; bleeding complications related to hypoprothrombinaemia or platelet dysfunction; GI effects; CNS toxicity; superinfection; pain at Inj site (IM); thrombophloebitis (IV infusion); hepatitis; cholestatic jaundice.
Potentially Fatal: Pseudomembranous colitis.
Drug Interactions
Disulfiram-like reaction with alcohol; may enhance hypoprothrombinemic response to anticoagulants; renal clearance reduced by probenecid.
Lab Interference
Transient increases in liver enzyme values; false-positive reactions for glucose using copper-reduction reactions; positive direct Coombs' test. May produce falsely high values in Jaffe method of measuring creatinine concentration.
Action
Cefmetazole has similar spectrum of activity to that of cefoxitin, and includes Bacteroides fragilis.
Distribution: 65-85% bound to plasma proteins.
Excretion: Plasma half-life: 1.1-1.5 hr. Prolonged in renally impaired patients. Excreted unchanged in the urine.
CIMS Class
ATC Classification
J01DC09 - cefmetazole ; Belongs to the class of second-generation cephalosporins. Used in the systemic treatment of infections.
Disclaimer: This information is independently developed by CIMS based on cefmetazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in